Premium
The effect of endocrine therapy with medroxyprogesterone acetate, 4‐hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin‐like growth factor (IGF)‐I, IGF‐II and IGFBP‐1 in women with advanced breast cancer
Author(s) -
Reed M. J.,
Christodoulides A.,
Koistinen R.,
Seppälä M.,
Teale J. D.,
Ghilchik M. W.
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910520209
Subject(s) - tamoxifen , endocrinology , medicine , medroxyprogesterone acetate , medroxyprogesterone , insulin like growth factor , antiestrogen , breast cancer , chemistry , growth factor , somatomedin , estrogen , cancer , receptor
Tamoxifen treatment of women with advanced breast cancer has previously been reported to reduce plasma insulin‐like growth factor‐type I (IGF‐I) concentrations. In this study we have examined the effect of treatment with Tamoxifen, medroxyprogesterone acetate (MPA) or 4‐hydroxyandrostenedione (4‐OHA) on plasma IGF‐I and IGF‐II concentrations. As IGF‐binding proteins (IGFBPs) can modulate the biological effects of IGF‐I, plasma IGFBP‐I levels were also measured. Treatment with Tamoxifen for 2 weeks resulted in a small, but significant, decrease in IGF‐I levels, but increase in the plasma concentration of IGFBP‐I. In contrast, treatment with MPA increased levels of IGF‐I, but significantly reduced plasma IGFBP‐I concentrations. Treatment with 4‐OHA had no significant overall effect on plasma IGF‐I or IGFBP‐I levels, although changes were detected for some subjects. Plasma IGF‐II concentrations were not altered by treatment with Tamoxifen, MPA or 4‐OHA. It is concluded that although treatment with Tamoxifen or MPA produced significant changes in plasma IGF‐I concentrations, any physiological effects of such changes are likely to be modulated by the corresponding alterations in plasma IGFBP‐I concentrations. © 1992 Wiley‐Liss, Inc.